In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
Eli Lilly has begun stockpiling approximately $1.5 billion worth of Orforglipron in advance of an expected FDA decision, signaling confidence in the oral GLP-1 therapy’s potential and preparing for immediate market launch if approved.
PTC Therapeutics has withdrawn its NDA for Translarna and intends to resubmit the application after addressing agency feedback. The move delays potential approval for the treatment, which targets patients with nonsense mutation Duchenne muscular dystrophy.
In international news, a former AstraZeneca executive in China has been formally charged with several offenses, highlighting ongoing scrutiny of corporate compliance and governance practices within multinational pharmaceutical operations abroad.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
